Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 16898 | 5.3548 |
09:34 ET | 4984 | 5.34 |
09:36 ET | 11623 | 5.32 |
09:38 ET | 4459 | 5.36 |
09:39 ET | 1120 | 5.41 |
09:41 ET | 1804 | 5.46 |
09:43 ET | 24547 | 5.5 |
09:45 ET | 4222 | 5.535 |
09:48 ET | 17362 | 5.45 |
09:50 ET | 5862 | 5.49 |
09:52 ET | 1329 | 5.47 |
09:54 ET | 2127 | 5.5197 |
09:56 ET | 1000 | 5.55 |
09:57 ET | 17522 | 5.58 |
09:59 ET | 7760 | 5.6 |
10:01 ET | 6013 | 5.6756 |
10:03 ET | 5085 | 5.61 |
10:06 ET | 3478 | 5.62 |
10:08 ET | 10135 | 5.65 |
10:10 ET | 13041 | 5.65 |
10:12 ET | 7398 | 5.64 |
10:14 ET | 1850 | 5.64 |
10:15 ET | 9350 | 5.63 |
10:17 ET | 7900 | 5.7 |
10:19 ET | 9246 | 5.72 |
10:21 ET | 5326 | 5.7367 |
10:24 ET | 5188 | 5.71 |
10:26 ET | 4669 | 5.68 |
10:28 ET | 8800 | 5.66 |
10:30 ET | 7375 | 5.6302 |
10:32 ET | 3868 | 5.66 |
10:33 ET | 1131 | 5.65 |
10:35 ET | 9275 | 5.68 |
10:37 ET | 2878 | 5.7399 |
10:39 ET | 3011 | 5.76 |
10:42 ET | 5749 | 5.73 |
10:44 ET | 5462 | 5.7013 |
10:46 ET | 2591 | 5.72 |
10:48 ET | 5500 | 5.72 |
10:50 ET | 24599 | 5.68 |
10:51 ET | 10330 | 5.71 |
10:53 ET | 22632 | 5.79 |
10:55 ET | 26049 | 5.8 |
10:57 ET | 3354 | 5.815 |
11:00 ET | 2320 | 5.76 |
11:02 ET | 14716 | 5.8 |
11:04 ET | 23309 | 5.78 |
11:06 ET | 4582 | 5.7366 |
11:08 ET | 25021 | 5.73 |
11:09 ET | 1635 | 5.75 |
11:11 ET | 12263 | 5.73 |
11:13 ET | 400 | 5.73 |
11:15 ET | 13559 | 5.69 |
11:18 ET | 15074 | 5.682 |
11:20 ET | 16278 | 5.6103 |
11:22 ET | 4500 | 5.62 |
11:24 ET | 935 | 5.62 |
11:26 ET | 7145 | 5.59 |
11:27 ET | 3387 | 5.61 |
11:29 ET | 3229 | 5.63 |
11:31 ET | 809 | 5.63 |
11:33 ET | 2378 | 5.62 |
11:36 ET | 2258 | 5.61 |
11:38 ET | 994 | 5.59 |
11:40 ET | 2864 | 5.62 |
11:42 ET | 9196 | 5.63 |
11:44 ET | 1300 | 5.62 |
11:45 ET | 3388 | 5.585 |
11:47 ET | 1600 | 5.58 |
11:49 ET | 1612 | 5.53 |
11:51 ET | 2006 | 5.54 |
11:54 ET | 2001 | 5.56 |
11:56 ET | 1800 | 5.565 |
11:58 ET | 2615 | 5.54 |
12:00 ET | 4820 | 5.54 |
12:02 ET | 600 | 5.56 |
12:03 ET | 879 | 5.57 |
12:05 ET | 1781 | 5.56 |
12:07 ET | 1978 | 5.5619 |
12:09 ET | 2200 | 5.58 |
12:12 ET | 1200 | 5.57 |
12:14 ET | 2785 | 5.54 |
12:16 ET | 3267 | 5.52 |
12:18 ET | 3120 | 5.56 |
12:20 ET | 300 | 5.55 |
12:21 ET | 1708 | 5.53 |
12:23 ET | 2008 | 5.545 |
12:25 ET | 4610 | 5.5699 |
12:27 ET | 200 | 5.58 |
12:30 ET | 648 | 5.58 |
12:32 ET | 900 | 5.56 |
12:34 ET | 3022 | 5.55 |
12:36 ET | 600 | 5.56 |
12:38 ET | 600 | 5.54 |
12:39 ET | 3008 | 5.58 |
12:41 ET | 3608 | 5.57 |
12:43 ET | 3410 | 5.57 |
12:45 ET | 2102 | 5.59 |
12:48 ET | 1331 | 5.56 |
12:50 ET | 2220 | 5.57 |
12:52 ET | 4796 | 5.55 |
12:54 ET | 1169 | 5.57 |
12:56 ET | 1796 | 5.56 |
12:57 ET | 1589 | 5.58 |
12:59 ET | 1199 | 5.57 |
01:01 ET | 747 | 5.56 |
01:03 ET | 3728 | 5.55 |
01:06 ET | 800 | 5.5401 |
01:08 ET | 500 | 5.5581 |
01:10 ET | 3974 | 5.54 |
01:12 ET | 1375 | 5.55 |
01:14 ET | 1039 | 5.549 |
01:15 ET | 1600 | 5.56 |
01:17 ET | 100 | 5.57 |
01:19 ET | 2183 | 5.56 |
01:21 ET | 550 | 5.5638 |
01:24 ET | 3192 | 5.55 |
01:26 ET | 3204 | 5.57 |
01:28 ET | 1557 | 5.57 |
01:30 ET | 700 | 5.56 |
01:32 ET | 1187 | 5.6 |
01:33 ET | 2984 | 5.6 |
01:35 ET | 2202 | 5.6 |
01:37 ET | 1862 | 5.62 |
01:39 ET | 2141 | 5.62 |
01:42 ET | 1500 | 5.62 |
01:44 ET | 5751 | 5.59 |
01:46 ET | 1423 | 5.62 |
01:48 ET | 2284 | 5.62 |
01:50 ET | 400 | 5.62 |
01:51 ET | 1387 | 5.61 |
01:53 ET | 3367 | 5.6199 |
01:55 ET | 4143 | 5.63 |
01:57 ET | 3312 | 5.6 |
02:00 ET | 2617 | 5.58 |
02:02 ET | 8982 | 5.54 |
02:04 ET | 4495 | 5.55 |
02:06 ET | 600 | 5.55 |
02:08 ET | 2787 | 5.54 |
02:09 ET | 1052 | 5.53 |
02:11 ET | 1794 | 5.53 |
02:13 ET | 2296 | 5.52 |
02:15 ET | 14833 | 5.5 |
02:18 ET | 2343 | 5.52 |
02:20 ET | 200 | 5.53 |
02:22 ET | 2800 | 5.53 |
02:24 ET | 2620 | 5.53 |
02:26 ET | 700 | 5.53 |
02:27 ET | 2322 | 5.53 |
02:29 ET | 893 | 5.54 |
02:31 ET | 2720 | 5.52 |
02:33 ET | 700 | 5.51 |
02:36 ET | 2304 | 5.5 |
02:38 ET | 800 | 5.51 |
02:40 ET | 2397 | 5.53 |
02:42 ET | 1000 | 5.54 |
02:44 ET | 1971 | 5.53 |
02:45 ET | 600 | 5.53 |
02:47 ET | 2200 | 5.53 |
02:49 ET | 402 | 5.54 |
02:51 ET | 1870 | 5.55 |
02:54 ET | 1395 | 5.54 |
02:56 ET | 3676 | 5.55 |
02:58 ET | 2003 | 5.58 |
03:00 ET | 1503 | 5.57 |
03:02 ET | 3524 | 5.56 |
03:03 ET | 2874 | 5.555 |
03:05 ET | 3670 | 5.56 |
03:07 ET | 562 | 5.55 |
03:09 ET | 1605 | 5.53 |
03:12 ET | 5878 | 5.57 |
03:14 ET | 2010 | 5.56 |
03:16 ET | 1325 | 5.56 |
03:18 ET | 4609 | 5.558 |
03:20 ET | 600 | 5.55 |
03:21 ET | 4828 | 5.53 |
03:23 ET | 700 | 5.53 |
03:25 ET | 9838 | 5.52 |
03:27 ET | 12382 | 5.49 |
03:30 ET | 1168 | 5.52 |
03:32 ET | 3269 | 5.53 |
03:34 ET | 4968 | 5.53 |
03:36 ET | 20570 | 5.58 |
03:38 ET | 2500 | 5.61 |
03:39 ET | 5337 | 5.58 |
03:41 ET | 3401 | 5.6 |
03:43 ET | 4716 | 5.6 |
03:45 ET | 19955 | 5.61 |
03:48 ET | 2200 | 5.6 |
03:50 ET | 4021 | 5.62 |
03:52 ET | 10907 | 5.63 |
03:54 ET | 18273 | 5.6001 |
03:56 ET | 16723 | 5.565 |
03:57 ET | 21774 | 5.54 |
03:59 ET | 139666 | 5.55 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 189.1M | -1.6x | --- |
Trevi Therapeutics Inc | 190.2M | -7.8x | --- |
Design Therapeutics Inc | 191.0M | -3.2x | --- |
Candel Therapeutics Inc | 179.7M | -4.8x | --- |
Pyxis Oncology Inc | 198.5M | -2.3x | --- |
Outlook Therapeutics Inc | 178.6M | -0.6x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $189.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -1.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.